BPC-157
BPC-157 is a synthetic 15-amino-acid peptide whose sequence corresponds to a fragment described in the literature as deriving from a protein found in gastric juice. It is studied almost exclusively in preclinical tissue-repair, angiogenesis and gastrointestinal model systems. BPC-157 is not an approved medicine in any major jurisdiction, and VaultLabs supplies it as a lyophilised reference material for in vitro laboratory research only.
Research use only. For in vitro research use only. Not for human or animal consumption. Not for human consumption, medical use, or personal application.
Reviewed by VaultLabs Research Editorial Desk · Last updated 2026-08-03
Key facts
- A synthetic pentadecapeptide — fifteen residues — with CAS registry number 137525-51-0.
- Molecular formula C62H98N16O22; molecular weight 1419.55 g/mol.
- Published work is overwhelmingly preclinical: rodent injury models and cell-culture assays. No regulator has approved BPC-157 as a medicine.
- BPC-157 is prohibited in sport by the World Anti-Doping Agency, which is a relevant compliance fact for any laboratory working with athletes or sports bodies.
- VaultLabs releases each lot against an HPLC purity specification with a lot-linked certificate of analysis.
- Chemical name
- BPC-157 (body protection compound 157)
- Common synonyms
- Pentadecapeptide BPC-157, PL 14736
- Sequence length
- 15 amino acids
- CAS number
- 137525-51-0
- Molecular formula
- C62H98N16O22
- Molecular weight
- 1419.55 g/mol
- Appearance
- White lyophilised powder
- Catalog strength
- 10 mg vial
What BPC-157 is
BPC-157 is a fully synthetic peptide of fifteen residues. The name refers to body protection compound, the term used in the original research programme for a protein fraction identified in gastric juice; the marketed peptide is a synthetic sequence corresponding to a fragment of that material, not an extract.
At 1419.55 g/mol it sits at the larger end of what is conventionally handled as a small peptide. It is supplied lyophilised because the dry state is far more stable than solution, and because lyophilisation allows an accurate fill weight to be certified per vial.
The sequence contains no cysteine, so it has no disulfide bridge to preserve — a practical advantage in handling compared with cyclic peptides such as oxytocin. It remains susceptible to the usual degradation routes for peptides in solution: hydrolysis, proteolysis if contamination is introduced, and damage from repeated freeze-thaw cycling.
Where the research literature sits
The BPC-157 literature originates largely from a Croatian research programme beginning in the 1990s and has since broadened. Published studies concentrate on rodent models of tendon, ligament, muscle and gastrointestinal injury, and on cell-culture assays measuring migration, angiogenic markers and inflammatory signalling.
It is important to characterise this evidence accurately. It is preclinical. Reports of healing in a rat tendon transection model or of accelerated closure in a scratch assay describe those systems and nothing beyond them. There are very few controlled human studies, and BPC-157 has not been approved as a medicine by the UAE Ministry of Health and Prevention, the FDA, the EMA, or any comparable authority.
A separate and often overlooked fact is its anti-doping status: BPC-157 is on the World Anti-Doping Agency prohibited list. Laboratories connected to sports medicine, testing programmes or athlete populations should treat that as a compliance constraint on how material is stored, logged and accounted for.
Analytical characterisation and what the certificate shows
Each lot is released against a reversed-phase HPLC purity specification. Because BPC-157 is a popular target for misrepresentation in the wider market, the chromatogram matters more than the label: it should show a dominant peak at the expected retention behaviour and no unexplained secondary peaks at meaningful area percent.
Where mass confirmation is available for a lot, it is the strongest single piece of identity evidence, because a peptide of the wrong length or with a substituted residue can still produce a clean-looking chromatogram. Laboratories with LC-MS access frequently run an incoming-goods confirmation regardless of the supplied certificate.
Every VaultLabs certificate is tied to the lot number on the vial and retrievable through batch verification. A certificate that cannot be matched to a specific lot in a supplier's published records should be treated as unverified.
Handling, reconstitution and stability
Store sealed lyophilised vials at 2–8 °C, protected from light and moisture. Allow the vial to equilibrate to room temperature before breaking the seal so that humid air does not condense onto the cake — a real consideration in Gulf laboratories where ambient humidity is high.
After reconstitution the practical stability window is short and depends on diluent, temperature and how often the vial is opened. Bacteriostatic water is the usual choice where a preparation will be drawn from more than once; sterile water suits single-session use. Record the reconstitution date, the diluent and each freeze-thaw cycle in the laboratory notebook.
Do not assume a solution remains at its certified purity. The certificate characterises the lyophilised material as released. Everything after the seal is broken is governed by your own handling, and long-running experiments should build in a re-check rather than relying on the original figure.
Regulatory position and permitted use
BPC-157 is not a registered medicine in the United Arab Emirates and is not supplied by VaultLabs for human or veterinary use. Orders are accepted only on a research-use basis, and the declaration made at checkout is retained as part of the order record.
Institutional buyers are responsible for their own approvals, controlled-substance and import obligations, and internal ethics processes. VaultLabs provides lot-linked certificates, research-use invoicing and batch records to support that documentation, but the permitted use determination belongs to the receiving institution.
How VaultLabs supplies BPC-157
The catalog presentation is a 10 mg lyophilised vial. Each vial carries a lot identifier resolving to a published certificate where one has been uploaded for that batch, and stock is held under controlled cold storage before dispatch across the UAE.
BPC-157 also appears as a component of the KLOW multi-peptide blend. Laboratories evaluating the blend should review the documentation for each constituent separately, since a composite material cannot carry a single meaningful purity figure for all of its components.
Research interest areas
Tendon and ligament fibroblast models
GI mucosal repair assays (in vitro)
Angiogenesis marker studies
Inflammatory pathway panels
Wound-healing scratch assays
Storage information
2–8 °C (lyophilized, sealed)
2–8 °C sealed storage for lyophilized material. Document reconstitution date and storage conditions for any prepared solutions per institutional SOP.
Stability notes
Lyophilized BPC-157 maintains integrity when stored sealed under recommended cold conditions. Avoid repeated moisture exposure before reconstitution.
In vitro molecular registry
Registry entry for BPC-157 (Body Protection Compound-157). Specifications are resolved from the same source that generates the product page and the certificate of analysis.
| Chemical name | BPC-157 (Body Protection Compound-157) |
|---|---|
| CAS Registry Number | 137525-51-0 |
| Molecular formula | C62H98N16O22 |
| Average molecular weight | 1419.55 g/mol |
| Amino acid sequence | 15-amino-acid gastric pentadecapeptide |
| Synonyms | Pentadecapeptide BPC-157, PL 14736 |
| Purity specification | 99.91% |
| Analytical method | HPLC |
| Appearance | White lyophilized powder |
| Product code | VL-BPC-157-10 |
| Regulatory status | For in vitro laboratory research use only — not for human or animal consumption |
Chain architecture
A linear synthetic pentadecapeptide of fifteen residues, corresponding to a partial sequence of a protein isolated from gastric juice. The chain is prepared by solid-phase synthesis and contains no cysteine, so no intramolecular disulfide bridge forms and disulfide scrambling is absent from its degradation profile. The absence of cyclisation gives it a conformationally flexible backbone, which is reflected in broader chromatographic peak shape than constrained cyclic peptides of comparable mass.
Historical characterisation and entry into the analytical literature
The sequence was characterised by Croatian peptide research groups during the 1990s as a fragment of a larger gastric protein, and entered the analytical literature under the laboratory designation PL 14736 alongside the descriptive name Body Protection Compound-157. Subsequent published work is predominantly preclinical: rodent injury models and cell-culture systems. Its widespread availability as a synthetic reference standard, combined with a well-defined mass and the absence of disulfide complexity, established it as a common test article in peptide analytical method development independently of the biological literature that produced it.
Receptor and pathway vectors reported in the literature
Pathways characterised in published preclinical and in vitro assay literature. No affinity constants are stated: values reported without their assay conditions are not comparable, and VaultLabs has not determined them independently.
- Angiogenesis-associated signalling pathways in cultured endothelial systems, as characterised in preclinical model literature
- Fibroblast proliferation and migration endpoints in in vitro scratch and monolayer assays
- Nitric oxide pathway markers reported in cell-culture model systems
- Growth-factor receptor expression panels in preclinical tissue-model literature
Use as an in vitro laboratory reference standard
- Reversed-phase HPLC system-suitability standard for mid-length linear peptides
- Identity control in LC-MS method qualification, where the calculated mass fully determines the expected charge-state envelope
- Ultraviolet response calibration at 214 nm for backbone amide detection
- Characterised comparator in preclinical receptor-binding and cell-based screening assays
- Reference article in forced-degradation studies of linear peptide backbones
Chromatographic and spectrometric behaviour
Elutes as a well-retained single peak on a C18 column under a standard water–acetonitrile gradient with trifluoroacetic acid modifier. In positive-mode electrospray it produces a clean multiply protonated series, and because the sequence contains no cysteine there is no reduced-versus-oxidised ambiguity to resolve during mass confirmation.
Stability profile
Stable as a sealed lyophilized solid under standard cold storage. In aqueous solution the principal routes are backbone amide hydrolysis and deamidation at asparagine and glutamine positions through the cyclic succinimide intermediate, both pH- and temperature-dependent. Prepared stocks should be aliquoted and frozen rather than held as a single refrigerated volume.
This registry entry describes analytical and preclinical in vitro laboratory context only. The material is an analytical reference material supplied strictly for in vitro laboratory research use only. It is not a medicine, food supplement or cosmetic, and it is not for human or animal consumption.
Selected literature
Named papers behind the statements on this page. Each entry resolves on PubMed and through its DOI, so you can read the source rather than take our summary of it. Inclusion describes the research record and is not a claim about this material’s suitability for any use.
Stable gastric pentadecapeptide BPC 157 and wound healing
Seiwerth S, et al. · Frontiers in Pharmacology · 2021
Review from the originating research programme, covering the rodent injury models that make up most of the evidence base.
Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review
Vasireddi N, et al. · HSS Journal · 2025
Independent systematic review; useful for its assessment of how thin the controlled human evidence remains.
Databases and verification
Registry and database entries for independent identity checks. These are standing searches rather than fixed records, so they stay current as new work is indexed.
- CAS Common Chemistry — 137525-51-0 — CAS
- PubChem record for BPC-157 — PubChem
- Indexed preclinical literature on BPC-157 — PubMed
- WADA Prohibited List (BPC-157 is a prohibited substance in sport) — World Anti-Doping Agency